These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 23535992)

  • 1. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
    Gutenberg A; Lumenta CB; Braunsdorf WE; Sabel M; Mehdorn HM; Westphal M; Giese A
    J Neurooncol; 2013 Jun; 113(2):163-74. PubMed ID: 23535992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
    Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
    Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
    Pan E; Mitchell SB; Tsai JS
    J Neurooncol; 2008 Jul; 88(3):353-7. PubMed ID: 18389176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating BCNU wafers into malignant glioma treatment: European case studies.
    Balossier A; Dörner L; Emery E; Heese O; Mehdorn HM; Menei P; Singh J
    Clin Drug Investig; 2010; 30(3):195-204. PubMed ID: 20155992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
    Burri SH; Prabhu RS; Sumrall AL; Brick W; Blaker BD; Heideman BE; Boltes P; Kelly R; Symanowski JT; Wiggins WF; Ashby L; Norton HJ; Judy K; Asher AL
    J Neurooncol; 2015 Jun; 123(2):259-66. PubMed ID: 25947286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
    Sabel M; Giese A
    Curr Med Res Opin; 2008 Nov; 24(11):3239-57. PubMed ID: 18940042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
    Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
    Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
    Dixit S; Hingorani M; Achawal S; Scott I
    Br J Neurosurg; 2011 Aug; 25(4):459-69. PubMed ID: 21344976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
    Roux A; Caire F; Guyotat J; Menei P; Metellus P; Pallud J;
    Neurochirurgie; 2017 Dec; 63(6):433-443. PubMed ID: 29122306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
    Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
    Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
    McPherson CM; Gerena-Lewis M; Breneman JC; Warnick RE
    J Neurooncol; 2012 Jul; 108(3):521-5. PubMed ID: 22467191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
    Miglierini P; Bouchekoua M; Rousseau B; Hieu PD; Malhaire JP; Pradier O
    Clin Neurol Neurosurg; 2012 Nov; 114(9):1222-5. PubMed ID: 22464950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
    Raizer JJ; Malkin MG; Kleber M; Abrey LE
    Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
    McGirt MJ; Than KD; Weingart JD; Chaichana KL; Attenello FJ; Olivi A; Laterra J; Kleinberg LR; Grossman SA; Brem H; Quiñones-Hinojosa A
    J Neurosurg; 2009 Mar; 110(3):583-8. PubMed ID: 19046047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymeric drug delivery for the treatment of glioblastoma.
    Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL
    Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
    Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.
    Kleinberg L
    Core Evid; 2012; 7():115-30. PubMed ID: 23118709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.